HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $7 to $2.5.
HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $7 to $2.5.